B Cells in Idiopathic Pulmonary Fibrosis: Targeting Immune Cells with Antifibrotic Agents.
作者信息
Roman Jesse, Chiba Hirofumi
机构信息
The Jane & Leonard Korman Respiratory Institute Thomas Jefferson University Philadelphia, Pennsylvania.
Department of Respiratory Medicine and Allergology Sapporo Medical University School of Medicine Sapporo, Japan.
出版信息
Am J Respir Cell Mol Biol. 2021 Jun;64(6):652-654. doi: 10.1165/rcmb.2021-0101ED.
Abstract
摘要
相似文献
1
B Cells in Idiopathic Pulmonary Fibrosis: Targeting Immune Cells with Antifibrotic Agents.特发性肺纤维化中的B细胞：用抗纤维化药物靶向免疫细胞
Am J Respir Cell Mol Biol. 2021 Jun;64(6):652-654. doi: 10.1165/rcmb.2021-0101ED.
2
Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.特发性肺纤维化患者在接受抗纤维化治疗前后用力肺活量下降的预后意义。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620953783. doi: 10.1177/1753466620953783.
3
Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.单中心真实世界经验：吡非尼酮治疗特发性肺纤维化和特发性非特异性间质性肺炎纤维化患者的疗效。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963015. doi: 10.1177/1753466620963015.
4
Comment on: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis.
Eur Respir J. 2021 Mar 18;57(3). doi: 10.1183/13993003.04645-2020. Print 2021 Mar.
5
Pirfenidone treatment of idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化。
Ther Adv Respir Dis. 2012 Apr;6(2):107-14. doi: 10.1177/1753465812436663. Epub 2012 Feb 14.
6
Reply: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis.
Eur Respir J. 2021 Mar 18;57(3). doi: 10.1183/13993003.00283-2021. Print 2021 Mar.
7
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.吡非尼酮治疗特发性肺纤维化（CAPACITY）患者的两项随机试验。
Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13.
8
Combination therapies targeting multiple pathways in idiopathic pulmonary fibrosis (IPF).
Intern Med. 2013;52(22):2481-2. doi: 10.2169/internalmedicine.52.0847.
9
[Antifibrotic treatment].[抗纤维化治疗]
Dtsch Med Wochenschr. 2014 Dec;139(49):2523-5. doi: 10.1055/s-0034-1387450. Epub 2014 Nov 25.
10
Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience.抗纤维化药物治疗患者的慢性纤维性间质性肺炎急性加重：真实世界经验中的发生率和风险因素。
BMC Pulm Med. 2019 Jun 25;19(1):113. doi: 10.1186/s12890-019-0880-0.
引用本文的文献
1
Pulmonary fibrosis: pathogenesis and therapeutic strategies.肺纤维化：发病机制与治疗策略。
MedComm (2020). 2024 Sep 23;5(10):e744. doi: 10.1002/mco2.744. eCollection 2024 Oct.
2
Cellular and Molecular Genetic Mechanisms of Lung Fibrosis Development and the Role of Vitamin D: A Review.细胞和分子遗传机制在肺纤维化发展中的作用及维生素 D 的影响：综述。
Int J Mol Sci. 2024 Aug 16;25(16):8946. doi: 10.3390/ijms25168946.
3
Single-cell sequencing analysis fibrosis provides insights into the pathobiological cell types and cytokines of radiation-induced pulmonary fibrosis.单细胞测序分析纤维化提供了对放射性肺纤维化的病理生物学细胞类型和细胞因子的深入了解。
BMC Pulm Med. 2023 Apr 28;23(1):149. doi: 10.1186/s12890-023-02424-5.
4
Potential of resveratrol in the treatment of interstitial lung disease.白藜芦醇在间质性肺疾病治疗中的潜力。
Front Pharmacol. 2023 Apr 6;14:1139460. doi: 10.3389/fphar.2023.1139460. eCollection 2023.
5
Immunophenotyping of Acute Inflammatory Exacerbations of Lung Injury Driven by Mutant Surfactant Protein-C: A Role for Inflammatory Eosinophils.由突变表面活性蛋白C驱动的肺损伤急性炎症加重的免疫表型分析：炎症性嗜酸性粒细胞的作用
Front Pharmacol. 2022 Apr 27;13:875887. doi: 10.3389/fphar.2022.875887. eCollection 2022.
本文引用的文献
1
Antifibrotics Modify B-Cell-induced Fibroblast Migration and Activation in Patients with Idiopathic Pulmonary Fibrosis.抗纤维化药物可改变特发性肺纤维化患者中 B 细胞诱导的成纤维细胞迁移和激活。
Am J Respir Cell Mol Biol. 2021 Jun;64(6):722-733. doi: 10.1165/rcmb.2020-0387OC.
2
Aberrant populations of circulating T follicular helper cells and regulatory B cells underlying idiopathic pulmonary fibrosis.特发性肺纤维化患者循环滤泡辅助 T 细胞和调节性 B 细胞的异常。
Respir Res. 2019 Nov 6;20(1):244. doi: 10.1186/s12931-019-1216-6.
3
Enhanced Bruton's tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis.B 细胞中增强的 Bruton 酪氨酸激酶和特发性肺纤维化患者的自身反应性 IgA。
Respir Res. 2019 Oct 24;20(1):232. doi: 10.1186/s12931-019-1195-7.
4
Transcriptional regulatory model of fibrosis progression in the human lung.人类肺部纤维化进展的转录调控模型。
JCI Insight. 2019 Nov 14;4(22):131597. doi: 10.1172/jci.insight.131597.
5
The therapy of idiopathic pulmonary fibrosis: what is next?特发性肺纤维化的治疗：下一步是什么？
Eur Respir Rev. 2019 Sep 4;28(153). doi: 10.1183/16000617.0021-2019. Print 2019 Sep 30.
6
Idiopathic Pulmonary Fibrosis.特发性肺纤维化
N Engl J Med. 2018 May 10;378(19):1811-1823. doi: 10.1056/NEJMra1705751.
7
Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets.特发性肺纤维化：上皮-间充质相互作用和新的治疗靶点。
Matrix Biol. 2018 Oct;71-72:112-127. doi: 10.1016/j.matbio.2018.03.021. Epub 2018 Apr 3.
8
Canonical Stimulation of the NLRP3 Inflammasome by Fungal Antigens Links Innate and Adaptive B-Lymphocyte Responses by Modulating IL-1β and IgM Production.真菌抗原对NLRP3炎性小体的经典刺激通过调节IL-1β和IgM的产生将先天性和适应性B淋巴细胞反应联系起来。
Front Immunol. 2017 Nov 9;8:1504. doi: 10.3389/fimmu.2017.01504. eCollection 2017.
9
Microbiome in interstitial lung disease: from pathogenesis to treatment target.间质性肺疾病中的微生物组：从发病机制到治疗靶点
Curr Opin Pulm Med. 2017 Sep;23(5):404-410. doi: 10.1097/MCP.0000000000000399.
10
Microbial Antigens Stimulate Metalloprotease-7 Secretion in Human B-Lymphocytes Using mTOR-Dependent and Independent Pathways.微生物抗原通过 mTOR 依赖和非依赖途径刺激人 B 淋巴细胞分泌金属蛋白酶-7。
Sci Rep. 2017 Jun 20;7(1):3869. doi: 10.1038/s41598-017-04199-2.
Zotero 插件